Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214825 · ClinicalTrials.gov registry record · NA
Aldosterone and Vascular Disease in Diabetes Mellitus
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT00214825: Completed NA study, sponsored by Brigham and Women's Hospital.
NCT00214825 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00214825, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
Specific aims for this proposal are to determine in patients with diabetes mellitus the effects of an aldosterone receptor antagonist on: 1. Coronary microvascular function assessed by MRI perfusion reserve, 2. Endothelial dysfunction assessed by brachial artery reactivity studies, and 3. Inflammation assessed by blood measurements of c-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1).
Interventions
- DRUG Hydrochlorothiazide
- DRUG eplerenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-03 |
| Phase | NA |
What the finished NCT00214825 record still lists
NCT00214825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide is the first listed.
NCT00214825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00214825 about?
NCT00214825 is a clinical study titled "Aldosterone and Vascular Disease in Diabetes Mellitus". Specific aims for this proposal are to determine in patients with diabetes mellitus the effects of an aldosterone receptor antagonist on: 1. Coronary microvascular function assessed by MRI perfusion reserve, 2. Endothelial dysfunction assessed by brachial artery reactivity studies, and 3. Inflammat...
What is the current status of trial NCT00214825?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2003-08. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00214825?
The interventions under investigation include: Hydrochlorothiazide (DRUG), eplerenone (DRUG).
Who is sponsoring clinical trial NCT00214825?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00214825's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia